Amyloid fibril formation in microwell plates for screening of inhibitors

Amyloid

Volumn 8, Issue 3, 2001, Pages 182-193

  Lin, Y M ^a   Raffen, R ^a   Zhou, Y ^a   Cassidy, C S ^a   Flavin, M T ^a   Stevens, F J ^a  

^a DeCODE Chemistry & Biostructures   (United States)

Author keywords

Fibril formation; LEN VL inhibitor; Microwell plate assay

Indexed keywords

AMYLOID; BIFLAVONOID; CHALCONE; FLAVONOID;

ALZHEIMER DISEASE; AMYLOIDOSIS; ARTICLE; ATHEROSCLEROSIS; BLOOD DYSCRASIA; CONCENTRATION (PARAMETERS); DIABETES MELLITUS; IMMUNOPATHOLOGY; MOLECULAR MODEL; PRIORITY JOURNAL; SICKLE CELL ANEMIA;

EID: 0034807861     PISSN: 13506129     EISSN: None     Source Type: Journal    
DOI: 10.3109/13506120109007361     Document Type: Article

References (67)

1. Conformational disease
2. Amyloidosis: A final common pathway for protein deposition in tissues
3. Amyloidosis
4. Amyloid plaque and diabetes
5. The spectrum of monoclonal immunoglobulin deposition disease associated with immunocytic dyscrasias
6. Monoclonal immunoglobulin deposition disease: Light chain and light and heavy chain deposition diseases and their relation to light chain amyloidosis
7. Fanconi's syndrome, kappa light-chain myeloma, non-amyloid fibrils and cytoplasmic crystals in renal tubular epithelium
8. Bence Jones proteins: A powerful tool for the fundamental study of protein chemistry and pathophysiology
9. Monoclonal Ig L chain and L chain V domain fragment crystallization in myeloma-associated Fanconi's syndrome
10. Ominous consequences of immunoglobulin deposition
11. Toward understanding the molecular pathogenesis of monoclonal immunoglobulin light-chain deposition
12. Structural and functional characterization of three human immunoglobulin κ light chains with different pathological implications
13. Molecular anatomy and the pathological expression of antibody light chains
14. Biology and therapy of immunoglobulin deposition diseases
15. 1-42 are potent central nervous system neurotoxins
16. Role of the β-amyloid protein in Alzheimer's disease
17. Physicochemical consequences of amino acid variations that contribute to fibril formation by immunoglobulin light chains
18. Four structural risk factors identify most fibril-forming kappa light chains
19. Chapter 3. β-amyloid as a target for Alzheimer's disease therapy
20. Modified-peptide inhibitors of amyloid β-peptide polymerization
21. Synthesis and evaluation of anthranilic acid-based transthyretin amyloid fibril inhibitors
22. Discovering transthyretin amyloid fibril inhibitors by limited screening
23. β-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for Alzheimer's therapy
24. Aβ-deposition inhibitor screen using synthetic amyloid
25. Treatment of AL amyloidosis with 4′-iodo-4′-deoxydoxorubicin: An update
26. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease
27. Light chains of human immunoglobulins
28. The characterization of soluble amyloid prepared in water
29. Recombinant immunoglobulin variable domains generated from synthetic genes provide a system for in vitro characterization of light chain amyloid proteins
30. Light chain-associated amyloid deposits comprised of a novel κ constant domain
31. Fluorometric determination of amyloid fibrils in vitro using the fluorescent dye
32. Heterocyclic compounds of chalcone type
33. Synthesis of halogenoflavonoids I. Synthesis of 6-chloro-flavanone and -flavone
34. Synthesis of halogenoflavonoids II. Synthesis of 2′,3′,4′-chloro-flavanone and -flavone
35. Synthesis of halogenoflavonoids III. Synthesis of 2′-, 3′-, 4′-, 6-bromoflavanones and 6-bromoflavones
36. Synthesis of halogenoflavonoids IV. Synthesis of 2′-, 3′-, 4′-iodoflavanone and corresponding chalcones
37. Synthesis of halogenoflavonoids VII. Synthesis of 2-, 3- and 4-fluoro-2′-oxychalcone
38. Biflavonyls from drupes of Rhus succedanea
39. Agathisflavone from drupes of Rhus succedanea
40. Robustaflavone from the seed of kernels of Rhus succedanea
41. Rhusflavanone, a new biflavanone from the seeds of wax tree
42. Variable domain structure of κIV human light chain LEN: High homology to the murine light chain McPC603
43. Quantifying amyloid β-peptide (Aβ) aggregation using the Congo red Aβ (CR- Aβ) spectrophotometric assay
44. First-order kinetic model of Alzheimers β-amyloid fibril extension in vitro
45. Thioflavine T interaction with synthetic Alzheimer's disease β-amyloid peptides: Detection of amyloid aggregation in solution
46. Thioflavine T interaction with amyloid β-sheet structures
47. Methodological and chemical factors affecting amyloid β-peptide amyloidogenicity
48. Models of amyloid seeding in Alzheimer's disease and scrapie-mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins
49. Monitoring protein assembly using quasielastic light scattering spectroscopy
50. Flow cytometric characterization of amyloid fibrils
51. Stopped-flow kinetics reveal multiple phases of Thioflavin T binding to Alzheimer β (1-40) amyloid fibrils
52. Quantification of β-sheet amyloid fibril structures with Thioflavin T
53. Kinetic analysis of amyloid fibril formation
54. Amyloid β-protein flbrillogenesis - Structure and biological activity of protofibrillar intermediates
55. β-amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity
56. Solvent effects on self-assembly of β-amyloid peptide
57. Domain stability in immunoglobulin light chain deposition disorders
58. Lectins as chaperones in glycoprotein folding
59. The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways
60. Protein misfolding, evolution and disease
61. Thermodynamic modulation of light chain amyloid fibril formation
62. Formation of an active dimer during storage of interleukin-1 receptor antagonist in aqueous solution
63. A transient expansion of the native state precedes aggregation of recombinant human interferon-gamma
64. Inhibiting transthyretin amyloid fibril formation via protein stabilization
65. Inhibiting transthyretin conformational changes that lead to amyloid fibril formation
66. Pathogenic light chains and the B-cell repertoire
67. Inhibition of amyloid fiber assembly by both BiP and its target peptide